The FDA has granted a Fast Track Designation to onvansertib for the second-line treatment of patients with KRAS-mutant metastatic colorectal cancer (mCRC) in combination with FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) and bevacizumab (Avastin), according to a press release from Cardiff Oncology, Inc. “We are very pleased with the FDA’s decision to grant Fast Track designation for […]

While many Massachusetts companies officially opened their doors this week after temporarily closing over COVID-19 concerns, one Boston-area biotech company has developed a tool to keep workers safe as the pandemic persists. “I was thinking, ‘While we’re going to leave [the office], that means at some point we’re going to come back. How does that work?’” […]

Officials with the FDA have granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). Fast Track designation is intended to facilitate development and expedite review of drugs to address an unmet medical need in the […]